Ipsen returns to profit, with drug sales up 2.1%
Full-year 2013 group revenues at French drugmaker Ipsen (Euronext: IPN) came in at 1.28 billion euros ($17.59 billion), a rise of 0.3%, although drug sales increased 2.1% to 1.19 billion euros, the company reported this morning. The company’s shares dipped 1.4% to 30.76 euros in morning trading.
Operating profit leapt 62.9% to 190.7 million euros, and consolidated profit was 153.1 million euros compared with a loss of 27.5 million euros in 2012, when it exited the hemophilia market. Earnings per share were 1.83 euros, versus a loss of 0.33 euros. Recurring adjusted fully diluted EPS was 1.85 euros compared with 1.76 euros, up 5.1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze